Effect of Oral Sildenafil With Digital Therapeutic Iontophoresis of Sodium Nitroprussiate in Healthy Volunteers
Iontophoresis is a employed to facilitate drug absorption without systemic effect. This study investigates cutaneous microcirculation when we associate sildenafil per os with SNP via iontophoresis...
Brief Summary
Official Title: “Effect of Oral Sildenafil With Digital Therapeutic Iontophoresis of Sodium Nitroprussiate on Cutaneous Blood Flow in Healthy Volunteers”
Iontophoresis is a employed to facilitate drug absorption without systemic effect. This study investigates cutaneous microcirculation when we associate sildenafil per os with SNP via iontophoresis.
- Study Type: Interventional
- Study Design: Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
- Study Primary Completion Date: June 2011
Detailed Clinical Trial Description
The main outcome is the proof of concept of effect of systemic absorption sildenafil on cutaneous microcirculation associated with SNP iontophoresis.
Intervention(s) in this Clinical Trial
- Drug: sildenafil
- systemic absorption of sildenafil
- Drug: nitroprussiate iontophoresis
- nitroprussiate iontophoresis
Arms, Groups and Cohorts in this Clinical Trial
- Experimental: 1
- Active Comparator: 2
- SNP iontophoresis
Outcome Measures for this Clinical Trial
Primary Measures
- variation of conductance of nitroprussiate iontophoresis associated with oral sildenafil
- Time Frame: one hour
Safety Issue?: No
- Time Frame: one hour
Secondary Measures
- To assess the effect of oral sildenafil (50 mg and 100 mg) on skin microvascular reactivity to local cooling, on the forearm and the finger
- Time Frame: one hour
Safety Issue?: No
- Time Frame: one hour
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Age over 18
- No significant medical history
Exclusion Criteria:
- Age under 18
- Period of exclusion for an other study
- Pregnancy
- Breast feeding
- Severe disease
- Cigarette smoking
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: Accepts Healthy Volunteers
Clinical Trial Investigator Information
Lead Investigator: University Hospital, Grenoble Other
Overall Clinical Trial Officials and Contacts
Jean-Luc CRACOWSKI, MD Principal Investigator Institut National de la Santé Et de la Recherche Médicale, France
Related Publications
References
Cracowski JL, Minson CT, Salvat-Melis M, Halliwill JR. Methodological issues in the assessment of skin microvascular endothelial function in humans. Trends Pharmacol Sci. 2006 Sep;27(9):503-8. Epub 2006 Jul 31. Review.
Additional Information
Information obtained from ClinicalTrials.gov on February 12, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00710099
Study ID Number: DCIC/08/08
ClinicalTrials.gov Identifier: NCT00710099
Health Authority: France: Afssaps - French Health Products Safety Agency
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00710099
